Jiang Bingya, Li Shufen, Zhao Wei, Li Ting, Zuo Lijie, Nan Yanni, Wu Linzhuan, Liu Hongyu, Yu Liyan, Shan Guangzhi, Zuo Limin
Key Laboratory of Biotechnology of Antibiotics of Ministry of Health, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100050, People's Republic of China.
J Nat Prod. 2014 Sep 26;77(9):2130-3. doi: 10.1021/np500138k. Epub 2014 Aug 25.
A new granaticin analogue and its hydrolysis product were isolated from Streptomyces sp. CPCC 200532. Their structures were determined to be 6-deoxy-13-hydroxy-8,11-dione-dihydrogranaticins B (1) and A (2), respectively, by detailed analysis of spectroscopic data. Compound 1 was regarded as an intermediate in granaticin biosynthesis, as it was bioconvertable to granaticin B. Compared to granaticin B, 1 showed similar cytotoxicity against cancer cell line HCT116, but decreased cytotoxicity against cancer cell lines A549, HeLa, and HepG2. Compound 2 displayed lower cytotoxicity than 1 against all four cancer cell lines tested.
从链霉菌属CPCC 200532中分离出一种新的Granaticin类似物及其水解产物。通过对光谱数据的详细分析，确定它们的结构分别为6-脱氧-13-羟基-8,11-二酮-二氢Granaticin B（1）和A（2）。化合物1被认为是Granaticin生物合成的中间体，因为它可以生物转化为Granaticin B。与Granaticin B相比，1对癌细胞系HCT116表现出相似的细胞毒性，但对癌细胞系A549、HeLa和HepG2的细胞毒性降低。化合物2对所有四种测试癌细胞系的细胞毒性均低于1。
